A massive genetic study found that naturally lower cholesterol is linked to a dramatically reduced risk of dementia. The ...

Two widely available medicines can safely improve brain health in those with early Alzheimer’s disease, a new study has found ...

The team found a notable correlation between genetics that predicted low cholesterol and a lower risk of dementia, suggesting ...

These biotech IPOs plan to move forward during shutdown © 2025 American City Business Journals. All rights reserved. Use of ...

Health Canada has authorized a drug shown to slow the progression of Alzheimer's disease. Lecanemab is the first medication ...

Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...

Controversial anti-amyloid therapies costing up to $32,000 annually offer modest hope for Alzheimer's patients while carrying ...

An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage ...

Village Caregiving reports that in-home care for seniors with dementia fosters independence, safety, and companionship, ...

The NDA submission is supported by data from two pivotal Phase 3 clinical trials, which evaluated MK-6240’s performance in detecting tau pathology in early Alzheimer’s disease. These studies met their ...

Scientists do not fully understand what causes the chronic neurodegenerative disease Alzheimer's, but they are examining a ...

However, lecanemab doesn’t stop the relentless march of Alzheimer’s disease, it just slows it down. The medication, sold under the brand name Leqembi, also comes with a hefty price tag and a risk of ...